| Literature DB >> 31155540 |
Motoki Kawasaki1, Mitsuru Ito1, Hirosuke Danno1, Kazuyoshi Kousaka1, Tomohiko Nakamura1, Waka Yoshioka1, Toshihiko Kasahara1, Takumi Kudo1, Eijun Nishihara1, Shuji Fukata1, Mitsushige Nishikawa1, Hirotoshi Nakamura1, Nagaoki Toyoda2, Akira Miyauchi1.
Abstract
While patients with large goitrous thyroid diseases often have a relatively high serum free triiodothyronine (FT3)/free thyroxine (FT4) ratio, athyreotic patients have a relatively low FT3/FT4 ratio. Here we investigated the relationship between thyroid hormone status and thyroid volume (TV) among a large number of euthyroid Hashimoto thyroiditis (HT) patients. We retrospectively enrolled 2,603 untreated HT patients who visited the Kuma hospital from 2012 to 2016, and divided them into four groups as per the TV: normal TV (<20 mL), slight goiter (20 ≤ TV < 50 mL), moderate goiter (50 ≤ TV < 80 mL), and the large goiter group (≥80 mL). Baseline characteristics and laboratory data of each group were compared to those of 1,554 control subjects. The association between FT3/FT4 ratio and TV among HT patients was then analyzed. We observed a change in laboratory parameters among 13 patients in the large goiter group who were prescribed levothyroxine (LT4) for reducing TV. Compared to normal subjects, the moderate and large goiter groups exhibited significantly higher serum FT3 levels, while all HT groups exhibited lower serum FT4 levels. Serum FT3/FT4 ratios showed a positive correlation with TV (r = 0.35, p < 0.01), which was independent of age, sex, body mass index, and TgAb and TSH levels. LT4 treatment lowered serum FT3 levels and FT3/FT4 ratios significantly. Our results indicated that HT patients with increased TV tended to present with high serum FT3, low FT4, and high FT3/FT4 ratios. The elevation of deiodinase activity may be an important factor affecting thyroid hormonal balance in such patients.Entities:
Keywords: Deiodinase; FT3/FT4 ratio; Hashimoto thyroiditis; Thyroid hormone; Thyroid volume
Mesh:
Substances:
Year: 2019 PMID: 31155540 DOI: 10.1507/endocrj.EJ19-0063
Source DB: PubMed Journal: Endocr J ISSN: 0918-8959 Impact factor: 2.349